Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome.

Trial Profile

Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2013

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 25 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 Results presented at the Digestive Disease Week 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top